Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Nikita Monakhov has a total of 63 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Psychosocial and behavioral characteristics of HIV-infected men who have sex with men

    by Chirskaya M.A. Chirskaya, Khalezova N.B. Khalezova, Monakhov N.E. Monakhov, Sereda E.ZH. Sereda, Myagkova O.S. Myagkova, Rusina E.A. Rusina, Vinogradova T.N. Vinogradova, Saint Petersburg Saint Petersburg Center For The Prevention And Control Of Aids And Infectious Diseases

  • Open Access

    Psychosocial and psychopathological features of HIV-positive men who engage in high‑risk behavior

    by M. A. Chirskaya, N. B. Khalezova, E. Zh. Sereda, N. E. Monakhov, M. S. Vorobyova, E. A. Rusina, M. V. Kukushina

    The aim : to assess the mental, psychological, and social characteristics of men with risky behavior in a cohort of people living with HIV (PLWH). Materials and methods . 114 men infected with the human immunodeficiency virus (HIV) via male-to-male sexual contact were examined. The clinical-anamnestic method (medical record review), laboratory tests, and an experimental-psychological method in the form of questionnaires were used. Results and discussion . According to our study, 76% of the men had higher, unfinished higher, or vocational/secondary education, and 90% were actively employed. The mean duration of follow-up at the Center for the Prevention and Control of AIDS and Infectious Diseases (AIDS Center) was 5.2±4.5 years. Virological success of antiretroviral therapy (ART) (HIV RNAConclusion . HIV-infected MSM demonstrate low psychological resilience and require the development and implementation of comprehensive prevention and support programs.

  • HIV-1 drug resistance profile in patients with inefficient antiretroviral therapy containing elsulfavirine

    by A. A. Kirichenko, D. E. Kireev, A. V. Kravchenko, I. A. Lapovok, N. V. Sizova, N. E. Monakhov, A. I. Ermakov, M. V. Pitersky, A. V. Semenov, M. R. Bobkova, et al.

    The aim . To determine the HIV-1 drug resistance profile in patients with virological failure to elsulfavirine-containing antiretroviral therapy in a real-world clinical setting. Materials and methods . The study group consisted of HIV-1 nucleotide sequences ( pol gene fragments encoding protease and part of reverse transcriptase) from 179 HIV-infected patients with virological failure of elsulfavirine-containing antiretroviral therapy and who had not previously received other non-nucleoside reverse transcriptase inhibitors. Resistance mutations were identified and HIV-1 drug resistance was determined using the HIVdb database (v. 9.8). Results and discussion . HIV-1 mutations associated with viral resistance to non-nucleoside reverse transcriptase inhibitors were detected in 88.3% of patients with virological failure of elsulfavirine-containing antiretroviral therapy. Previously described HIV-1 resistance profiles to elsulfavirine were detected in only 5.1% of the studied patients. A total of 29 mutations were detected, the most common being V106I (46.9%), E138K (38.5%), H221Y (34.6%), E138Q (20.7%), F227C (12.3%), Y181C (11.7%), K101E (11.2%), and E138A (10.6%). A total of 87 different HIV-1 mutation patterns were detected, with combinations of two or more mutations predominating (70.9%). The main patterns detected included combinations of mutations V106I/M, E138K/Q/G, and H221Y±K101E, F227C, G190S, and M230L. High levels of HIV-1 resistance in the studied patients were most frequently detected to rilpivirine (60.9%), which limits its successful use in patients taking elsulfavirine, and least frequently to doravirine (22.9%) and etravirine (9.5%), which allows them to be considered as options for switching. Conclusion . This study identified the main mutations associated with elsulfavirine-containing therapy failure, potential pathways for the development of HIV-1 resistance to the drug, and HIV-1 cross-drug resistance to other drugs in class. However, most of the patterns identified in this study have not been previously described, indicating the need to update data on the HIV1 resistance profile to elsulfavirine.

  • Acquired drug resistance of HIV in patients with virological failure of first-line art

    by N. E. Monakhov, E. A. Sharipova, S. V. Lapunova, T. N. Vinogradova, D. A. Lioznov

    Aim of the study: to assess quantitative and qualitative indicators of HIV drug resistance to antiretroviral drugs in patients with virological failure of first-line ART. Materials and methods . Clinical and laboratory parameters and results of HIV molecular genetic testing were analyzed in 964 patients with virological failure of antiretroviral therapy (ART) in 2018–2022 at the St. Petersburg AIDS Center. Fragments of the pol gene encoding HIV enzymes were examined by PCR and Sanger sequencing. Identification of HIV drug resistance mutations to antiretroviral therapy was performed using the Stanford University HIVDB algorithm Version 9.4.1. The dynamics of HIV resistance prevalence among ART recipients were assessed by comparing the results of two studies: a retrospective study (2006–2011) and a current study (2018–2022) in St. Petersburg. Results and discussion . Virological failure was associated with the development of HIV resistance mutations in 76.5% of patients. HIV resistance mutations were found in the majority of cases (93.9%) in patients receiving first-line ART. Regimens consisting of 2 nucleoside reverse transcriptase inhibitors (NRTI) + non-nucleoside reverse transcriptase inhibitors (NNRTI) combination were more frequently used (72.1%), the proportion of first-generation NNRTI class drugs was 58,7%. According to the results of HIV resistance testing, resistance to the NRTI (90.6%) and NNRTI (78.3%) classes was more common than to protease inhibitors (PI) (3.8%) and integrase strand transfer inhibitors (INSTI) (0.9%). HIV resistance to two drug classes was found in 74,2% of patients, most frequently to the NRTI+NNRTI classes (71.3%). Multidrug resistance to three drug classes (NRTI+NNRTI+PI) was rarely detected, only in 1.3% of patients. Analysis of HIV resistance to antiretroviral drugs in patients over time showed an increase in resistance to NRTIs (from 79.8% to 90.6%) and NNRTIs (from 60.4% to 78.3%), comparing the periods 2006–2011 and 2018–2022. There was also a decrease in the number of patients with resistance to PIs (from 19.9% to 3.8%). Conclusion . Our study shows that acquired HIV drug resistance was the leading cause of virological ineffectiveness of antiretroviral therapy between 2018 and 2022. Importantly, the majority of HIV drug resistance was observed in patients receiving first-line therapy. These findings highlight the need to modernize first-line ART regimens, including the wider introduction into clinical practice of drugs with a high genetic barrier to resistance. These include modern integrase inhibitors or protease inhibitors. The choice of ART regimen should be based on the patient’s previous drug history and HIV resistance indicators. When selecting a new regimen plan for patients with multidrug-resistant HIV, it is essential to use at least two or three medications (typically from different classes) that do not have any resistance mutations.


  • Open Access

    The Molecular Epidemiology of HIV-1 in Russia, 1987–2023: Subtypes, Transmission Networks and Phylogenetic Story

    by Aleksey Lebedev, Dmitry Kireev, Alina Kirichenko, Ekaterina Mezhenskaya, Anastasiia Antonova, Vyacheslav Bobkov, Ilya Lapovok, Anastasia Shlykova, Alexey Lopatukhin, Andrey Shemshura, et al.

    Regional HIV-1 epidemics are evolving with distinct patterns in transmission routes, subtype distribution, and molecular transmission cluster (MTCs) characteristics. We analyzed 9500 HIV-1 cases diagnosed over 30 years using phylogenetic and network methods, integrating molecular, epidemiological, demographic, and behavioral data. Subtype A6 remains dominant nationally (80.6%), followed by 63_02A6 (7.9%), subtype B (5.6%), 02_AGFSU (1.2%), 03_A6B (0.7%), and 14/73_BG (0.6%). Non-A6 infections were more common among males (OR 1.51) and men who have sex with men (OR 7.33). Network analysis identified 421 MTCs, with 256 active clusters. Clustering was more likely among young individuals (OR: 1.31), those not receiving antiretroviral therapy (OR: 2.70), and injecting drug users (OR: 1.28). Non-A6 subtypes showed a higher likelihood of clustering. Phylogenetic analysis revealed that local clusters of the major subtypes originated between the late 1970s (subtype B) and the mid-2000s (63_02A6) with links to populations in Eastern Europe, Central Asia (subtypes A6, 63_02A6, 02_AGFSU, 03_A6B), and Western Europe and the Americas (subtype B, 14/73_BG). These findings indicate a complex, evolving regional epidemic transitioning from subtype A6 dominance to a more diverse mix of subtypes. The ability of non-A6 subtypes to form active MTCs suggests their establishment in the local population.


  • Open Access

    Comparative analysis of socio-demographic characteristics of patients at the acute stage of HIV infection in the period 2008-2013 and 2018-2023

    by E. S. Obizhaeva, N. V. Sizova, O. N. Leonova, M. A. Chirskaya, N. E. Monakhov, E. Zh. Sereda, S. O. Maiorova

    Aim of the study: conducting a comparative analysis of the socio-demographic characteristics of patients with the acute phase of HIV infection at different periods of the epidemic with a difference of 10 years (2008–2013 and 2018–2022).Materials and methods. A retrospective analysis of 142 inpatient case histories of the Botkin Clinical Hospital and outpatient cards of the St. Petersburg AIDS Center of patients in whom HIV infection was detected in the period from 2008–2013 and 110 outpatient cards of patients in whom HIV infection was detected in 2018–2022 was carried out. A comparative assessment of social and epidemiological data of patients in the acute stage of HIV infection at different periods of the epidemic was carried out.Results and discussion. The social profile of a person who became infected with HIV in the period 2018–2022 has changed significantly compared to the period 10 years ago. The proportion of women has increased from 33% to 38%. The average age has increased from 32.5 to 35.9 years. The parenteral route of infection has significantly decreased from 23% to 5%. The percentage of officially employed people (from 68% to 91%) and those with higher education (from 27% to 45%) has increased.Conclusion. We conducted a comparative analysis of the socio-demographic characteristics of patients in the acute stage of HIV infection at different periods of the epidemic, as well as those infected in the periods 2008–2013 and 2018–2022. The data obtained indicate significant changes in the «portrait» of a person infected at the present stage. The average age of the patient has significantly increased. As a rule, this patient is employed and has a good education. All this must be taken into account when carrying out preventive measures.


  • Open Access

    Molecular genetic monitoring of HIV-1 variants circulating in St. Petersburg

    by N. E. Monakhov, A. I. Ermakov, E. S. Obizhaeva, T. N. Vinogradova, D. A. Lioznov

    The aim of the study: to assess the genetic diversity of HIV-1 variants circulating in St. Petersburg.Materials and methods. The study included 289 patients with virological ART failure in 2022 in the St. Petersburg AIDS Center. Fragments of the pol gene encoding integrase, reverse transcriptase and protease were analyzed by polymerase chain reaction and Sanger sequencing. Phylogenetic tree created by the Neighbor-joining method with 1000 repeats of nucleotide sequences, bootstrap values >70. To assess the circulation of HIV genovariants in dynamics in St. Petersburg, sequences and clinical and laboratory parameters obtained from 544 patients since 2018. The total sample included 833 samples (289 were collected in 2022), compared with the results of a study from 1104 HIV-infected patients in 2006–2011.Results and discussion. Monovariants of HIV dominated in the examined patients (95.1%, 275 people), subtype A6 — 88.2% (255 people); subtype B — 5.9% (17 people); C — 0.3% (1 person); G — 0.7% (2 people), the proportion of recombinant forms — 4.9% (14 people). In the sample collection, the proportion of new HIV cases of non-A subtype was 13.3% in 2006–2011, and 11.1% in 2018–2022. A significant increase in the incidence of recombinant forms of HIV-1 was revealed from 1.6% to 3.5% (c2=6.111; p=0.014). In the group (2018–2022), the recombinant form of CRF63_02A6 was more common (15/29 people).Conclusion. Phylogenetic analyses makes it possible to determine HIV subtypes, but also to establish the potential geographical origin of the virus, to identify transmission clusters taking into account the socio-demographic indicators of HIV-infected patients. Molecular epidemiological monitoring can be used to develop and implement programs to counter the spread of HIV among the population. The dominant genetic variant of HIV circulating in St. Petersburg is sub-subtype A6, as it was 10 years ago. The proportion of new cases of infection with non-A subtype of HIV remains stable, with a downward trend. The increase in the frequency of detection of recombinant forms of HIV-1 is probably related to the migration processes of the population.


  • Open Access

    Time-related changes in the titer of virus neutralizing antibodies against SARS-CoV-2 after COVID-19 in patients with HIV infection

    by O. E. Pobegalova, N. V. Kozmovskaya, N. E. Monakhov, A. N. Kholodnaya, D. M. Danilenko, T. V. Antonova, A. D. Lioznov

    Objective. To assess the time-related changes in the titer of virus neutralizing antibodies to SARS-CoV-2 in patients with HIV infection within 6 months after experienced COVID-19, and to identify factors associated with the intensity and duration of the natural humoral immune response.Materials and Methods. А prospective study was performed in 102 HIV-infected patients who had COVID-19 without previous vaccination, the titer of virus neutralizing antibodies to SARS-CoV-2 was identified by microneutralization assay using the standard method, the follow-up period was 6 months. Patients were enrolled in St. Petersburg from October 2020 to January 2022. The possible impact of clinical and laboratory characteristics of HIV infection and the severity of COVID-19 on antibody titer was assessed.Results and discussion. А high antibody titer (>1:160) was detected at 1 month in 15 patients (14.7%), at 3 months — in 5 of 44 patients; at 6 months — in 3 of 26 patients. There was a statistically significant positive correlation of the titer at 1 month with an undetectable HIV viral load and the Cd4+lymphocytes count in the blood. Cases of a late increase in antibody titer (after 3 and 6 months) were registered without COVID-19 re-infection along with improvement of the immune status on antiretroviral therapy.Conclusion. А low incidence of effective humoral immune response 1 month after COVID-19 infection was demonstrated in HIV-infected patients without vaccination against SARS-CoV-2. Single cases of delay in antibody titer increase with an immune status improvement were observed.

  • Open Access

    Reconstructing the Temporal Origin and the Transmission Dynamics of the HIV Subtype B Epidemic in St. Petersburg, Russia

    by Marina Siljic, Valentina Cirkovic, Luka Jovanovic, Anastasiia Antonova, Aleksey Lebedev, Ekaterina Ozhmegova, Anna Kuznetsova, Tatiyana Vinogradova, Aleksei Ermakov, Nikita Monakhov, et al.

    The HIV/AIDS epidemic in Russia is among the fastest growing in the world. HIV epidemic burden is non-uniform in different Russian regions and diverse key populations. An explosive epidemic has been documented among people who inject drugs (PWID) starting from the mid-1990s, whereas presently, the majority of new infections are linked to sexual transmission. Nationwide, HIV sub-subtype A6 (previously called AFSU) predominates, with the increasing presence of other subtypes, namely subtype B and CRF063_02A. This study explores HIV subtype B sequences from St. Petersburg, collected from 2006 to 2020, in order to phylogenetically investigate and characterize transmission clusters, focusing on their evolutionary dynamics and potential for further growth, along with a socio-demographic analysis of the available metadata. In total, 54% (107/198) of analyzed subtype B sequences were found grouped in 17 clusters, with four transmission clusters with the number of sequences above 10. Using Bayesian MCMC inference, tMRCA of HIV-1 subtype B was estimated to be around 1986 (95% HPD 1984–1991), whereas the estimated temporal origin for the four large clusters was found to be more recent, between 2001 and 2005. The results of our study imply a complex pattern of the epidemic spread of HIV subtype B in St. Petersburg, Russia, still in the exponential growth phase, and in connection to the men who have sex with men (MSM) transmission, providing a useful insight needed for the design of public health priorities and interventions.